title: Eosinophil viability-enhancing activity in mite-sensitive bronchial asthma.
abstract: We examined the eosinophil viability-enhancing activity (EVEA) of peripheral blood mononuclear cells (PBMNCs) obtained from 6 patients with mite-sensitive bronchial asthma (BA) and 9 normal control subjects. Mite concentrations of 1 microgram/ml and 10 micrograms/ml significantly increased EVEA in PBMNC culture supernatants from BA patients compared with PBMNCs from normal control subjects (76.1 +/- 11.0% at 10 micrograms/ml and 56.3 +/- 16.0% at 1 microgram/ml vs 20.6 +/- 12.6% at 10 micrograms/ml and 7.4 +/- 2.3% at 1 microgram/ml; p < 0.05). The level of IFN-gamma in PBMNC culture supernatants in BA patients was 2.3 +/- 0.9 IU/ml and in normal control subjects 0.7 +/- 0.3 IU/ml. A combination of mAbs (anti-IL-3, anti-IL-5 and anti-GM-CSF, with or without anti-IFN-gamma) neutralized the EVEA (p < 0.001, p < 0.001, respectively). Dexamethasone (10(-8) M to 10(-5) M), cyclosporin A (10(-7) M to 10(-5) M) and FK506 (10(-8) M to 10(-6) M) significantly inhibited EVEA in BA patients (p < 0.05 to p < 0.001). The release of eosinophil cationic protein (ECP) from eosinophils in the presence of mite-stimulated PBMNC culture supernatants was higher in patients with bronchial asthma (569 +/- 147 micrograms/l) than in normal control subjects (203 +/- 99 micrograms/l; p < 0.05).
authors.affiliation: First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto.
authors.forename: M
authors.initials: M
authors.lastname: Hossain
authors.forename: Y
authors.initials: Y
authors.lastname: Okubo
authors.forename: M
authors.initials: M
authors.lastname: Sekiguchi
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D000818:Animals; D001249:Asthma / Q000097:blood* / Q000276:immunology; D016022:Case-Control Studies; D015550:Cell Degranulation / Q000276:immunology; D002470:Cell Survival / Q000187:drug effects / Q000276:immunology; D016572:Cyclosporine / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D004804:Eosinophils / Q000187:drug effects / Q000276:immunology*; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000096:biosynthesis; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis; D007377:Interleukin-3 / Q000096:biosynthesis; D015848:Interleukin-5 / Q000096:biosynthesis; D007963:Leukocytes, Mononuclear / Q000276:immunology / Q000378:metabolism; D008875:Middle Aged; D008925:Mites / Q000276:immunology*; D016559:Tacrolimus / Q000494:pharmacology
chemical_list: D007377:Interleukin-3; D015848:Interleukin-5; D003907:Dexamethasone; D007371:Interferon-gamma; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D016572:Cyclosporine; D016559:Tacrolimus